Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Down 8% – Time to Sell?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares traded down 8% during trading on Wednesday . The company traded as low as $27.44 and last traded at $27.59. Approximately 256,776 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 375,752 shares. The stock had previously closed at $30.00.

Wall Street Analyst Weigh In

Several research firms have issued reports on DMRA. Evercore started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. HC Wainwright began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They issued a “buy” rating and a $45.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Finally, Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Performance

The company has a 50-day moving average of $24.07 and a 200-day moving average of $25.46. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -4.98 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $6,574,000. Jain Global LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,774,000. Remedium Capital Partners LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $2,204,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $266,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.